中脑周围蛛网膜下腔出血的血量与影像建议
该指南基于两项三级神经外科中心1999至2021年279例中脑周围蛛网膜下腔出血患者的回顾性分析,评估重复DSA的诊断获益与操作风险。结果显示血管病变检出率仅0.4%,而操作相关缺血性并发症发生率为2.5%;13 mL出血量阈值可较好区分出院预后。
要点
- 符合严格pmSAH标准且高质量CTA阴性者,常规重复DSA缺乏依据
- DSA操作并发症率超过血管病变检出率,需谨慎把握指征
- 初始平扫CT出血量13 mL阈值可辅助早期风险分层
核心结论
- 符合严格中脑周围蛛网膜下腔出血标准且高质量CTA阴性时,常规重复DSA不合理
- 操作相关并发症率超过诊断阳性检出率,重复DSA仅在临床恶化等特定情况下考虑
- 出血量13 mL阈值可辅助早期危险分层,但需进一步验证
研究设计与样本
- 回顾性分析1999至2021年2家三级神经外科中心279例连续pmSAH患者
- 评估人口学、临床严重程度、血管影像(CTA、DSA、MRA)、操作并发症及改良Rankin量表结局
- 中脑周围出血量在初始平扫CT可用时进行定量测量
关键影像表现/征象
- 初始平扫CT中脑周围出血量以13 mL为阈值,可区分出院预后良好与不良
- 出血量阈值13 mL对应AUC 0.826,特异性0.88,阴性预测值0.97
- 1例血管病变仅在临床恶化并重复DSA后才被检出
诊断标准与关键数值
- 血管病变总体检出率为0.4%(1/279),仅在临床恶化后重复DSA检出
- DSA相关缺血性并发症发生率为2.5%(7/279),导致永久性神经功能缺损0.4%(1/279)
- 出血量13 mL阈值(约登指数最优)区分出院预后不良与良好,AUC 0.826
- 出血量13 mL阈值对应特异性0.88,阴性预测值0.97
- 影像检查使用情况:CTA 254例91.0%,DSA 199例71.3%,MRA 55例19.7%
临床应用与阅片要点
- 对严格符合pmSAH标准且高质量CTA阴性患者,不推荐常规重复DSA
- 初始平扫CT出血量达13 mL阈值时,应警惕出院预后不良风险
- 重复DSA应保留给临床恶化或高度怀疑血管病变的特定病例
- 阅片时应在初始平扫CT上尽量量化中脑周围出血量以辅助早期分层
局限性
- 回顾性研究设计存在选择偏倚和信息偏倚可能
- 出血体积阈值来自单队列的约登最优截断,缺乏外部验证
- 仅2家三级神经外科中心数据,结果外推性受限
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND OBJECTIVES: Perimesencephalic subarachnoid hemorrhage (pmSAH) has a markedly better prognosis than aneurysmal subarachnoid hemorrhage. Despite advances in noninvasive imaging, the role of repeat digital subtraction angiography (DSA) after negative initial high-quality vascular imaging remains debated. We evaluated the diagnostic yield and procedural risk of DSA in a large bicenter pmSAH cohort.
METHODS: We retrospectively analyzed 279 consecutive patients with pmSAH treated at 2 tertiary neurosurgical centers between 1999 and 2021. Demographics, clinical severity, vascular imaging [computed tomography angiography (CTA)/DSA/magnetic resonance angiography], procedure-related complications, and functional outcome (modified Rankin Scale) were assessed. Perimesencephalic blood volume was quantified from initial noncontrast computed tomography when available.
RESULTS: The predominant clinical presentation was mild with favorable outcome, with a mean modified Rankin Scale at discharge of 1.07 (SD 1.05). Imaging included CTA in 254 patients (91.0%), DSA in 199 patients (71.3%), and magnetic resonance angiography in 55 patients (19.7%). Vascular pathology was identified in 1 patient (0.4%), detected only after clinical deterioration and repeat DSA. Procedure-related ischemic complications occurred in 7 patients (2.5%), resulting in permanent neurological deficit in 1 patient (0.4%). A volumetric 13-mL pmSAH-threshold (Youden optimal) reliably separated poor from favorable discharge outcome (area under the curve 0.826), with high specificity (0.88) and negative predictive value (0.97), indicating potential value for early clinical decision-making.
CONCLUSION: In patients meeting strict pmSAH criteria with negative high-quality CTA, routine repeat DSA seems unjustified given a procedural complication rate that exceeds diagnostic yield. Hemorrhage volume may support early risk stratification but warrants further validation.
引用
- Preuss-Hernández, Geiger, Navrátil, et al. Hemorrhage Volume and Imaging Recommendations: Factors for Decision Making in the Care of Patients With Perimesencephalic Subarachnoid Hemorrhage. Neurosurgery. 2026. PMID: 42683974. doi:10.1227/neu.0000000000004192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。